ArticleJournal of nanobiotechnology2025
Astragaloside IV- loaded biomimetic nanoparticles target IκBα to regulate neutrophil extracellular trap formation for sepsis therapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Gegen Flavonoids and Huangqi Saponins Combination Ameliorates Diabetic Nephropathy By Modulating the Gut-Kidney Axis and Regulating Macrophage Polarization.Applied biochemistry and biotechnology · 2026Article
- Article
- Immunological mechanisms and novel therapeutic strategies for sepsis‑associated acute kidney injury (Review).International journal of molecular medicine · 2026Review
- Astragaloside IV: A multipotent phytochemical for treating fibrotic diseases (Review).International journal of molecular medicine · 2026Review
- Precision immunomodulation of viral myocarditis: a spatiotemporal intervention paradigm based on smart biomaterials.Frontiers in immunology · 2026Review
- Article
- Delivery of TCM Monomers Using Blood Cell Membrane Coated Biomimetic Nanoparticles to Target CVD.International journal of nanomedicine · 2026Review
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
- Mitochondrial dysfunction in sepsis-induced immunoparalysis: from immune-cell metabolic reprogramming to clinical biomarkers.Frontiers in immunology · 2026Review
- Sequential eradication of bacterial persisters: integrating phytochemical pharmacology with microenvironment-responsive delivery strategies.Frontiers in microbiology · 2026Review
- Neutrophil Extracellular Traps in the Prognosis of Sepsis: A Current Update.Medicina (Kaunas, Lithuania) · 2025Review
- Macrophage polarization in disease therapy: insights from astragaloside IV and cycloastragenol.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study explored the novel mechanism of Astragaloside IV (As) in treating sepsis and its application through a biomimetic nano-delivery system (As@ZM). Sepsis, a condition of organ dysfunction caused by an abnormal host response to infection, poses a significant threat to global health due to its high mortality rate. Our findings revealed a new mechanism for As in treating sepsis, which involved the reduction of neutrophil extracellular traps (NETs) release, potentially related to As binding with IκBα to inhibit the activation of the NF-κB pathway. As treated neutrophils also improved the immune microenvironment by crosstalk with endothelial cells and lung epithelial cells. However, the stability and bioavailability of As limited its clinical application. To address this issue, we had developed a ZIF-8-based nano-delivery system that achieved targeted delivery through neutrophil membrane coating, significantly enhancing the therapeutic efficacy of As. The innovative design of As@ZM offered a new strategy for sepsis treatment, with the potential to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.